(Q36450868)

14 August 2017

1 reference

title

Transdermal delivery of drugs for urologic applications: basic principles and applications (English)

1 reference

14 August 2017

Victor W Nitti

1

1 reference

14 August 2017

Steven Sanders

2

1 reference

14 August 2017

David R Staskin

3

1 reference

14 August 2017

Roger R Dmochowski

4

1 reference

14 August 2017

Peter K Sand

5

1 reference

14 August 2017

Scott MacDiarmid

6

1 reference

14 August 2017

Howard I Maibach

7

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 April 2006

1 reference

14 August 2017

1 reference

14 August 2017

volume

67

1 reference

14 August 2017

issue

4

1 reference

14 August 2017

page(s)

657-664

1 reference

Monitoring serum concentrations for once-daily netilmicin dosing regimens

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.11.039

Effect of controlled-release delivery on the pharmacokinetics of oxybutynin at different dosages: severity-dependent treatment of the overactive bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.11.039

Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.11.039

Solvent effects in permeation assessed in vivo by skin surface biopsy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.11.039

Clinical Pharmacokinetics of Drugs Used to Treat Urge Incontinence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.11.039

Compliance with treatment regimens in chronic asymptomatic diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.11.039

The impact of reducing dose frequency on health outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.11.039

Transdermal drug delivery systems and skin sensitivity reactions. Incidence and management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.11.039

Transdermal drug delivery and cutaneous metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.11.039

Absorption, metabolism, and disposition of [14C]SDZ ENA 713, an acetylcholinesterase inhibitor, in minipigs following oral, intravenous, and dermal administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.11.039

Comparative in vivo evaluation of propranolol hydrochloride after oral and transdermal administration in rabbits

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.11.039

The 500 Dalton rule for the skin penetration of chemical compounds and drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.11.039

Skin adhesives and skin adhesion. 1. Transdermal drug delivery systems

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.11.039

The role of dihydrotestosterone in benign prostatic hyperplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.11.039

Optimising delivery systems for HRT

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.11.039

Inflammation as a cardiovascular risk factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.11.039

Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.11.039

Effects of estrogen with and without progestin on urinary incontinence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.11.039

Pharmacokinetics, metabolism, and saliva output during transdermal and extended-release oral oxybutynin administration in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.11.039

Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.11.039

Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.11.039

Transdermal patches: an unseen risk for harm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.11.039

Sexual development in a two-year-old boy induced by topical exposure to testosterone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.11.039

Pharmacokinetics and metabolism of transdermal oxybutynin: in vitro and in vivo performance of a novel delivery system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.11.039

Comparison of two estradiol transdermal systems (Oesclim 50 and Estraderm TTS 50). I. Tolerability, adhesion and efficacy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2005.11.039

10.1016/J.UROLOGY.2005.11.039

7 January 2021

Identifiers

DOI

1 reference

14 August 2017

1 reference